MA39422A - Modulateurs de cot et procédés d'utilisation associés - Google Patents

Modulateurs de cot et procédés d'utilisation associés

Info

Publication number
MA39422A
MA39422A MA039422A MA39422A MA39422A MA 39422 A MA39422 A MA 39422A MA 039422 A MA039422 A MA 039422A MA 39422 A MA39422 A MA 39422A MA 39422 A MA39422 A MA 39422A
Authority
MA
Morocco
Prior art keywords
modulators
toc
related usage
usage procedures
procedures
Prior art date
Application number
MA039422A
Other languages
English (en)
Other versions
MA39422B1 (fr
Inventor
Elizabeth M Bacon
Gayatri Balan
Chien-Hung Chou
Christopher T Clark
Jeromy J Cottell
Musong Kim
Thorsten A Kirschberg
John O Link
Gary Phillips
Scott D Schroeder
Neil H Squires
Kirk L Stevens
James G Taylor
William J Watkins
Nathan E Wright
Sheila M Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA39422A publication Critical patent/MA39422A/fr
Publication of MA39422B1 publication Critical patent/MA39422B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La présente description concerne en général les modulateurs de cot (cancer osaka thyroïde) et les méthodes d'utilisation et de fabrication de celles-ci.
MA39422A 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés MA39422B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17
EP16738976.6A EP3191470B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
MA39422A true MA39422A (fr) 2017-07-19
MA39422B1 MA39422B1 (fr) 2019-03-29

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39422A MA39422B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Country Status (40)

Country Link
US (7) US20170008905A1 (fr)
EP (3) EP3456717B1 (fr)
JP (6) JP6430060B2 (fr)
KR (5) KR102443575B1 (fr)
CN (3) CN109879859B (fr)
AU (5) AU2016290820B2 (fr)
BR (1) BR102016015656B1 (fr)
CA (1) CA2971640C (fr)
CL (1) CL2017003356A1 (fr)
CO (1) CO2017013351A2 (fr)
CR (1) CR20170599A (fr)
CU (1) CU20170172A7 (fr)
CY (1) CY1121750T1 (fr)
DK (1) DK3191470T3 (fr)
DO (1) DOP2017000311A (fr)
EA (1) EA036788B1 (fr)
EC (1) ECSP17084635A (fr)
ES (2) ES2734713T3 (fr)
HR (1) HRP20190853T1 (fr)
HU (1) HUE043310T2 (fr)
IL (4) IL274568B (fr)
LT (1) LT3191470T (fr)
MA (1) MA39422B1 (fr)
ME (1) ME03425B (fr)
MX (1) MX370984B (fr)
MY (1) MY196173A (fr)
NZ (2) NZ750707A (fr)
PE (1) PE20180462A1 (fr)
PH (2) PH12018500031A1 (fr)
PL (2) PL3456717T3 (fr)
PT (2) PT3456717T (fr)
RS (1) RS58639B1 (fr)
SA (1) SA517381350B1 (fr)
SG (1) SG11201702041PA (fr)
SI (2) SI3191470T1 (fr)
SV (1) SV2017005605A (fr)
TW (3) TWI748539B (fr)
UA (1) UA123010C2 (fr)
UY (1) UY36771A (fr)
WO (1) WO2017007689A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
WO2016057931A1 (fr) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy
US9815818B2 (en) 2015-07-06 2017-11-14 Gilead Sciences, Inc. Cot modulators and methods of use thereof
CA2971640C (fr) 2015-07-06 2020-09-22 Gilead Sciences, Inc. Modulateurs de cot et procedes d'utilisation associes
WO2018005435A1 (fr) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines utilisées comme modulateurs de cot et leurs méthodes d'utilisation
MX369307B (es) 2016-08-19 2019-11-05 Gilead Sciences Inc Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019065516A1 (fr) * 2017-09-26 2019-04-04 日本曹達株式会社 Composé quinoléine, et agent bactéricide pour application agricole et horticole
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
EP3752496B1 (fr) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
WO2019168874A1 (fr) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Compositions de difluorométhoxylation et de trifluorométhoxylation et leurs procédés de synthèse
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CA3148365A1 (fr) 2019-08-29 2021-03-04 Martin Bolli Derives d'alpha-d-galactopyranoside
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
KR20220161438A (ko) * 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
WO2021202688A1 (fr) * 2020-04-02 2021-10-07 Gilead Sciences, Inc. Procédé de préparation d'un composé inhibiteur de cot
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
WO2022184755A1 (fr) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
US20240285646A1 (en) * 2021-06-11 2024-08-29 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
EP4440702A1 (fr) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Composés thérapeutiques contre l'infection par le virus du vih
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
IT7819093A0 (it) 1977-01-10 1978-01-06 Ciba Geigy Prodotti antielmintici e loro impiego.
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
KR20010022781A (ko) 1997-08-28 2001-03-26 도쿠시마 히데이치 시아노아크릴레이트 화합물을 함유하는 공업용 항균·항진균제, 살조제(殺藻劑) 및 생물 부착 방지제
CA2336691C (fr) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands pour metaux et processus perfectionnes catalyses par des metaux bases sur ceux-ci
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
US6930100B2 (en) 2002-03-20 2005-08-16 Bristol-Myers Squibb Company Phosphate prodrugs of fluoroxindoles
CN100395237C (zh) 2003-03-03 2008-06-18 弗·哈夫曼-拉罗切有限公司 用作5－ht6调节剂的2,5－取代的四氢异喹啉
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007014258A (es) * 2005-05-18 2008-01-22 Wyeth Corp Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos.
CA2608540A1 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs 3-cyanoquinoline de la tpl2 kinase et procedes de production et d'utilisation associes
AU2006306146A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
EP2001480A4 (fr) 2006-03-31 2011-06-15 Abbott Lab Composés d'indazole
JP5599614B2 (ja) 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US8389544B2 (en) 2007-01-17 2013-03-05 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
KR101562347B1 (ko) * 2010-06-09 2015-10-22 티안진 헤메이 바이오-텍 컴퍼니 리미티드 시아노퀴놀린 유도체
JP6110787B2 (ja) 2011-05-10 2017-04-05 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
BR112014000267A2 (pt) 2011-07-04 2016-09-20 Bayer Ip Gmbh utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
DK2772482T3 (en) 2011-10-27 2016-06-06 Taisho Pharmaceutical Co Ltd azole derivative
PL3628320T3 (pl) 2011-11-11 2022-07-25 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
EP2911655A1 (fr) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
CN105814013A (zh) 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
WO2016007966A2 (fr) * 2014-07-11 2016-01-14 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
CN106714841A (zh) 2014-09-24 2017-05-24 吉利德科学公司 治疗肝病的方法
MX2017008417A (es) 2014-12-23 2017-09-28 Gilead Sciences Inc Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1).
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EP3597271A1 (fr) 2015-01-09 2020-01-22 Gilead Apollo, LLC Thérapie combinée à base d'un inhibiteur de l'acc utilisable en vue du traitement de la stéatose hépatique non alcoolique
CN107111844B (zh) 2015-01-16 2021-07-13 3M创新有限公司 用于选择网格动作以改善网格结果的系统和方法
US9815818B2 (en) * 2015-07-06 2017-11-14 Gilead Sciences, Inc. Cot modulators and methods of use thereof
CA2971640C (fr) 2015-07-06 2020-09-22 Gilead Sciences, Inc. Modulateurs de cot et procedes d'utilisation associes
EP3398598B1 (fr) 2015-12-31 2022-04-06 Hitgen Inc. Dérivé du sulfonamide, son procédé de préparation et son procédé d'utilisation
EP4364795A3 (fr) 2016-03-02 2024-08-14 Gilead Apollo, LLC Formes solides d'un inhibiteur d'acc de thiénopyrimidinedione et leurs procédés de production
EP3473715B1 (fr) 2016-06-21 2021-08-04 PHC Holdings Corporation Inhibiteur de catalase et procédé de mesure d'analyte utilisant un inhibiteur de catalase
WO2018005435A1 (fr) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines utilisées comme modulateurs de cot et leurs méthodes d'utilisation
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3053956C (fr) 2017-03-03 2024-04-23 Gilead Sciences, Inc. Procedes de preparation d'inhibiteurs d'acc et formes solides correspondantes
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
KR20190132515A (ko) 2017-04-12 2019-11-27 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하는 방법
CA3077273A1 (fr) 2017-10-06 2019-04-11 Gilead Sciences, Inc. Polytherapie comprenant un inhibiteur de l'acc
CA3129949C (fr) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
US20220143153A1 (en) 2019-03-08 2022-05-12 The Regents Of The University Of California Compositions and methods for treating acne
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
KR20220161438A (ko) 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
WO2021202688A1 (fr) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Procédé de préparation d'un composé inhibiteur de cot
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法

Also Published As

Publication number Publication date
PH12018500031B1 (en) 2018-07-09
DOP2017000311A (es) 2018-01-15
PE20180462A1 (es) 2018-03-06
CL2017003356A1 (es) 2018-07-06
JP6781221B2 (ja) 2020-11-04
PH12018500031A1 (en) 2018-07-09
UA123010C2 (uk) 2021-02-03
KR20200013120A (ko) 2020-02-05
IL274568B (en) 2022-07-01
IL274568A (en) 2020-06-30
KR20240008398A (ko) 2024-01-18
US20240254137A1 (en) 2024-08-01
EP3191470A1 (fr) 2017-07-19
PL3191470T3 (pl) 2019-08-30
CN109879859A (zh) 2019-06-14
CU20170172A7 (es) 2018-06-05
SI3191470T1 (sl) 2019-04-30
TWI634112B (zh) 2018-09-01
US20230002407A1 (en) 2023-01-05
US11066414B2 (en) 2021-07-20
CA2971640C (fr) 2020-09-22
IL293770B2 (en) 2023-07-01
CN114380799B (zh) 2024-10-01
PL3456717T3 (pl) 2021-10-25
EA201792613A1 (ru) 2018-06-29
AU2016290820B2 (en) 2019-03-07
JP2022082816A (ja) 2022-06-02
RS58639B1 (sr) 2019-05-31
ME03425B (fr) 2020-01-20
JP7138155B2 (ja) 2022-09-15
JP6906021B2 (ja) 2021-07-21
US20180237455A1 (en) 2018-08-23
IL256433A (en) 2018-02-28
TW201712005A (zh) 2017-04-01
KR20190045416A (ko) 2019-05-02
TWI748539B (zh) 2021-12-01
ES2872076T3 (es) 2021-11-02
AU2016290820A1 (en) 2018-01-18
MX2017004737A (es) 2017-06-19
BR102016015656B1 (pt) 2021-11-03
IL256433B (en) 2019-06-30
ES2734713T3 (es) 2019-12-11
CN114380799A (zh) 2022-04-22
NZ750707A (en) 2023-09-29
JP2024100865A (ja) 2024-07-26
PT3456717T (pt) 2021-05-26
TW201908305A (zh) 2019-03-01
CO2017013351A2 (es) 2018-05-21
EP3456717B1 (fr) 2021-03-17
JP6430060B2 (ja) 2018-11-28
AU2020257055A1 (en) 2020-11-12
KR102443575B1 (ko) 2022-09-16
US11905299B2 (en) 2024-02-20
IL293770B1 (en) 2023-03-01
SG11201702041PA (en) 2017-04-27
US20170152240A1 (en) 2017-06-01
EP3456717A1 (fr) 2019-03-20
LT3191470T (lt) 2019-05-10
IL293770A (en) 2022-08-01
IL266995B (en) 2020-05-31
CR20170599A (es) 2018-02-28
KR102073641B1 (ko) 2020-02-05
EA036788B1 (ru) 2020-12-21
CN107922390A (zh) 2018-04-17
DK3191470T3 (en) 2019-04-15
CA2971640A1 (fr) 2017-01-12
JP2021042252A (ja) 2021-03-18
AU2020257055B2 (en) 2022-03-31
CN109879859B (zh) 2022-01-25
WO2017007689A1 (fr) 2017-01-12
BR102016015656A2 (pt) 2020-09-24
CY1121750T1 (el) 2020-07-31
US20170008905A1 (en) 2017-01-12
TWI699361B (zh) 2020-07-21
EP3896064A1 (fr) 2021-10-20
KR20220129667A (ko) 2022-09-23
ECSP17084635A (es) 2018-01-31
AU2022204050A1 (en) 2022-06-30
MA39422B1 (fr) 2019-03-29
PT3191470T (pt) 2019-06-05
MX370984B (es) 2020-01-09
KR20180022982A (ko) 2018-03-06
EP3191470B1 (fr) 2019-02-27
US20200123172A1 (en) 2020-04-23
US9878995B2 (en) 2018-01-30
JP2019178178A (ja) 2019-10-17
AU2019203122A1 (en) 2019-05-30
IL266995A (en) 2019-07-31
CN107922390B (zh) 2019-05-10
AU2022204050B2 (en) 2024-04-18
PH12020551397A1 (en) 2021-08-16
MY196173A (en) 2023-03-17
UY36771A (es) 2017-01-31
NZ738525A (en) 2019-03-29
HUE043310T2 (hu) 2019-08-28
SA517381350B1 (ar) 2021-03-11
JP2018520161A (ja) 2018-07-26
HRP20190853T1 (hr) 2019-06-28
TW202114673A (zh) 2021-04-16
SV2017005605A (es) 2018-07-18
SI3456717T1 (sl) 2021-08-31
AU2024204902A1 (en) 2024-08-01
JP2018193405A (ja) 2018-12-06
AU2019203122B2 (en) 2020-10-01
US20190248807A1 (en) 2019-08-15
KR101974793B1 (ko) 2019-05-02

Similar Documents

Publication Publication Date Title
MA39422A (fr) Modulateurs de cot et procédés d'utilisation associés
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CR20200483A (es) Anticuerpos anti-hla-g y utilización de los mismos
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
DOP2023000172A (es) Moduladores de cot y métodos de uso de los mismos
MA39126B1 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA39141A1 (fr) Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation
MA39078A1 (fr) Anticorps anti-cd3 et méthodes d'utilisation
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA38492A1 (fr) Anticorps et immunoconjugués anti-b7-h4